文献速递中枢神经肿瘤放疗

双硫仑联合铜同步放化疗及替莫唑胺治疗新诊断胶质母细胞瘤的1/2期研究

A Phase 1/2 Study of Disulfiram and Copper With Concurrent Radiation Therapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-05-19

这项1/2期研究评估双硫仑联合铜(DSF/Cu)同步放疗和替莫唑胺治疗新诊断胶质母细胞瘤的安全性和初步疗效。33例患者中,DSF联合放疗和替莫唑胺的最大耐受剂量为375 mg/d;多数患者临床疗效有限,但BRAF突变患者观察到较好疗效,值得进一步研究。

要点

  • DSF联合放疗和替莫唑胺的最大耐受剂量为375 mg/d。
  • IDH突变和NF1突变队列的总生存和无进展生存与未用DSF/Cu的机构对照相比无显著差异。
  • 3例BRAF突变患者出现延长缓解,作者认为值得进一步研究。

核心结论

  • DSF联合放疗和替莫唑胺的最大耐受剂量为375 mg/d。
  • DSF/Cu对多数患者临床疗效有限。
  • BRAF突变胶质母细胞瘤观察到较好疗效,值得进一步研究。

研究设计与样本

  • 1/2期研究,评估DSF/Cu联合放疗和替莫唑胺治疗新诊断胶质母细胞瘤的安全性和初步疗效。
  • 患者接受标准放疗和替莫唑胺联合DSF(250-375 mg/d)及铜,随后辅助替莫唑胺联合DSF(500 mg/d)及铜。
  • 采用高效液相色谱-质谱法进行药代动力学分析,测定血浆和肿瘤中的药物浓度。
  • 共33例患者,中位随访26.0个月,包括12例IDH突变、9例NF1突变、3例BRAF突变和9例其他IDH野生型病例。
  • 1期组18例患者,2期组另15例患者接受250 mg/d治疗。

主要发现

  • 1期组剂量限制性毒性概率在250 mg/d为10%(95%CI,3%-29%),在375 mg/d为21%(95%CI,7%-42%)。
  • IDH突变和NF1突变队列与未用DSF/Cu的机构对照相比,总生存或无进展生存均无显著差异。
  • 3例BRAF突变患者出现延长缓解。
  • DSF/Cu的推测活性代谢物二乙基二硫代氨基甲酸酯-铜在血浆中检测到,但在肿瘤中未检测到。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出DSF/Cu对多数患者临床疗效有限。
  • 原文结论指出BRAF突变胶质母细胞瘤的较好疗效值得进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This phase 1/2 study aimed to evaluate the safety and preliminary efficacy of combining disulfiram and copper (DSF/Cu) with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM). METHODS AND MATERIALS: Patients received standard RT and TMZ with DSF (250-375 mg/d) and Cu, followed by adjuvant TMZ plus DSF (500 mg/d) and Cu. Pharmacokinetic analyses determined drug concentrations in plasma and tumors using high-performance liquid chromatography-mass spectrometry. RESULTS: Thirty-three patients, with a median follow-up of 26.0 months, were treated, including 12 IDH-mutant, 9 NF1-mutant, 3 BRAF-mutant, and 9 other IDH-wild-type cases. In the phase 1 arm, 18 patients were treated; dose-limiting toxicity probabilities were 10% (95% CI, 3%-29%) at 250 mg/d and 21% (95% CI, 7%-42%) at 375 mg/d. The phase 2 arm treated 15 additional patients at 250 mg/d. No significant difference in overall survival or progression-free survival was noted between IDH- and NF1-mutant cohorts compared with institutional counterparts treated without DSF/Cu. However, extended remission occurred in 3 BRAF-mutant patients. Diethyl-dithiocarbamate-copper, the proposed active metabolite of DSF/Cu, was detected in plasma but not in tumors. CONCLUSIONS: The maximum tolerated dose of DSF with RT and TMZ is 375 mg/d. DSF/Cu showed limited clinical efficacy for most patients. However, promising efficacy was observed in BRAF-mutant GBM, warranting further investigation.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Huang J, Campian JL, DeWees TA, et al. A Phase 1/2 Study of Disulfiram and Copper With Concurrent Radiation Therapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma. Int J Radiat Oncol Biol Phys. 2024. PMID: 38768767. doi:10.1016/j.ijrobp.2024.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。